BridgeBio Pharma and Kyowa Kirin Announce Partnership with an Upfront Payment of $100 Million for an Exclusive License on Infigratinib in Skeletal Dysplasias in Japan Feb 7, 2024 07:34AM
Kyowa Kirin to Acquire Orchard Therapeutics Oct 5, 2023 03:35AM
Ardelyx (ARDX) Announces Tenapanor for Hyperphosphatemia Approved in Japan Sep 25, 2023 06:56AM
Tenapanor for Hyperphosphatemia Approved in Japan Sep 25, 2023 04:15AM
MEI Pharma (MEIP) and Kyowa Kirin Announce Discontinuation of Zandelisib Development Outside of Japan Following Recent FDA Meeting Dec 5, 2022 05:03PM


Dec 5, 2022 05:00PM MEI Pharma and Kyowa Kirin Announce Discontinuation of Zandelisib Development Outside of Japan Following Recent FDA Meeting
Nov 3, 2022 09:00AM MEI Pharma and Kyowa Kirin Announce Acceptance of Three Abstracts for Presentation at the American Society of Hematology Annual Meeting 2022
Jul 18, 2022 08:00AM MEI Pharma and Kyowa Kirin Announce Publication in The Lancet Oncology of Data from Phase 1b Clinical Study of Zandelisib in Patients with Relapsed or Refractory B-cell Malignancy
Jun 10, 2022 03:00AM MEI Pharma and Kyowa Kirin Report Clinical Data on Zandelisib at European Hematology Association 2022 Hybrid Congress
Jun 4, 2022 04:00PM MEI Pharma and Kyowa Kirin Report New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2022
May 26, 2022 05:00PM MEI Pharma and Kyowa Kirin Announce Acceptance of Abstract for Presentation at the American Society of Clinical Oncology Annual Meeting 2022
May 12, 2022 10:00AM MEI Pharma and Kyowa Kirin Announce Acceptance of Two Abstracts for Presentation at the European Hematology Association 2022 Hybrid Congress
Dec 16, 2021 08:10AM InveniAI and Kyowa Kirin Expand AI-Driven Partnership to a Multi-Year Strategic Collaboration for the Discovery of Novel Targets and Treatments Across Therapeutic Areas
Oct 2, 2021 06:00AM Amgen And Kyowa Kirin Present Positive Late-Breaking Data From Phase 2 Study Of AMG 451/KHK4083 In Adult Patients With Moderate-to-Severe Atopic Dermatitis At EADV Congress
Oct 2, 2021 05:00AM Kyowa Kirin and Amgen Present Positive Late-Breaking Data from Phase 2 Study of KHK4083/AMG 451 in Adult Patients with Moderate-to-Severe Atopic Dermatitis at EADV Congress
Sep 13, 2021 09:00AM Amgen To Showcase New Data From Inflammation Portfolio At EADV Virtual Congress 2021
Aug 17, 2021 08:00AM MEI Pharma and Kyowa Kirin Announce First Patient Dosed in the Phase 3 COASTAL Study Evaluating Zandelisib Plus Rituximab in Relapsed or Refractory Indolent Non Hodgkin's B-cell Lymphoma
Jun 9, 2021 06:00AM MEI Pharma and Kyowa Kirin to Present Clinical Data from Ongoing Studies Evaluating Zandelisib for Lymphoma at the 16th International Conference on Malignant Lymphoma Virtual Scientific Program
Jun 1, 2021 04:00AM Amgen and Kyowa Kirin to Jointly Develop and Commercialize KHK4083, a Phase 3-Ready, Potential First-In-Class Treatment for Atopic Dermatitis
May 19, 2021 05:03PM MEI Pharma (MEIP) and Kyowa Kirin Announce New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2021
May 19, 2021 05:00PM MEI Pharma and Kyowa Kirin Announce New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2021
May 12, 2021 10:02AM MEI Pharma (MEIP), Kyowa Kirin to Present Clinical Data from Phase 1b Study of Zandelisib in Combination with Zanubrutinib at the European Hematology Association 2021 Virtual Congress
May 12, 2021 10:00AM MEI Pharma and Kyowa Kirin to Present Clinical Data from Phase 1b Study of Zandelisib in Combination with Zanubrutinib at the European Hematology Association 2021 Virtual Congress
Mar 25, 2021 08:29AM Twist Bioscience and Kyowa Kirin Partner for GPCR Antibody Discovery
Dec 10, 2019 04:30AM Kirin to Release “Slow Drink(R)” Advertisements Promoting Responsible Drinking in Pursuit of Zero Harmful Drinking During the Holiday Season
Nov 25, 2019 06:00PM Ardelyx and Kyowa Kirin Expand Partnership with Two Additional Agreements
Feb 7, 2019 06:30AM Ardelyx Collaboration Partner, Kyowa Hakko Kirin, Announces Initiation of a Phase 2 Clinical Study of Tenapanor for Hyperphosphatemia Patients on Dialysis in Japan
Nov 28, 2017 02:00AM Ardelyx and Kyowa Hakko Kirin Announce License Agreement for Tenapanor for Cardiorenal Diseases in Japan
Dec 5, 2016 07:51AM ArQule (ARQL) Announces Presentation of ARQ 092 Data in SCD at ASH 2016
Dec 5, 2016 06:13AM ArQule (ARQL) Presents ARQ 531 Data at ASH 2016
Dec 4, 2016 09:00PM Data on Proprietary BTK Inhibitor, ARQ 531, Demonstrating Inhibition of Wild Type and C481S Mutant BTK and Superiority to Ibrutinib in TCL1 Mouse Model Presented at the American Society of Hematology
Dec 3, 2016 05:45PM Preclinical Data on Proprietary AKT Inhibitor, ARQ 092, Demonstrating Effectiveness in the Treatment of Sickle Cell Disease Presented at the American Society of Hematology Annual Meeting
Nov 7, 2016 07:00AM ArQule Reports Third Quarter 2016 Financial Results
Nov 3, 2016 09:05AM Advancements in ArQule’s Proprietary Pipeline to be Highlighted at the 2016 American Society of Hematology Annual Meeting
Oct 24, 2016 07:00AM ArQule To Report Third Quarter 2016 Financial Results On November 7, 2016
Jun 6, 2016 06:37AM Pfizer (PFE) Announces Encouraging Safety Data from Utomilumab Combo Phase 1b in Adv. Solid Tumors
Jun 4, 2016 08:00AM Pfizer Presents Data from Phase 1b Trial Investigating Utomilumab (a 4-1BB agonist) in Combination with a Checkpoint Inhibitor
Oct 27, 2015 06:59AM Bristol-Myers Squibb Reports Third Quarter Financial Results
Jul 29, 2015 07:00PM Kyowa Hakko Kirin and Bristol-Myers Squibb Announce Immuno-Oncology Clinical Collaboration Studying Mogamulizumab and Opdivo (nivolumab) in Advanced Solid Tumors in the U.S.
May 22, 2015 04:22PM Amgen to terminate participation in co-development and commercialization of brodalumab
Mar 17, 2015 04:01PM Amgen To Present 10 Abstracts From Its Dermatology Portfolio At The 73rd Annual Meeting Of The American Academy Of Dermatology